Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Shares Issued (2016 - 2025)

Tg Therapeutics has reported Shares Issued over the past 8 years, most recently at $1.1 million for Q4 2025.

  • Quarterly results put Shares Issued at $1.1 million for Q4 2025, up 85.61% from a year ago — trailing twelve months through Dec 2025 was $1.5 million (up 65.32% YoY), and the annual figure for FY2025 was $1.5 million, up 65.32%.
  • Shares Issued for Q4 2025 was $1.1 million at Tg Therapeutics, up from $432000.0 in the prior quarter.
  • Over the last five years, Shares Issued for TGTX hit a ceiling of $45.9 million in Q2 2023 and a floor of -$44.8 million in Q4 2023.
  • Median Shares Issued over the past 5 years was $131500.0 (2021), compared with a mean of $343222.2.
  • Biggest five-year swings in Shares Issued: crashed 620.0% in 2022 and later soared 33927.41% in 2023.
  • Tg Therapeutics' Shares Issued stood at $2.0 million in 2021, then crashed by 112.98% to -$260000.0 in 2022, then plummeted by 17116.54% to -$44.8 million in 2023, then soared by 101.27% to $570000.0 in 2024, then skyrocketed by 85.61% to $1.1 million in 2025.
  • The last three reported values for Shares Issued were $1.1 million (Q4 2025), $432000.0 (Q2 2025), and $21000.0 (Q1 2025) per Business Quant data.